Cheapest Weight Loss Injections UK | From £135.00/Month
Cheapest Weight Loss Injections Monthly Cost UK
Takes less than 2 minutes to complete 100% online
Our Pricing
Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.
Mounjaro Weight Loss Injections (Tirzepatide) KwikPen
Wegovy (Semaglutide) Weight Loss Injection
Wegovy® Oral Tablets (Semaglutide Pill): PRE-ORDER
Monthly Cost UK: Cheapest Weight Loss Injections
Published on: June 03, 2026
Searching for the cheapest weight loss injections UK monthly cost options? At Cured Pharmacy, we offer transparent upfront pricing on all UK-licensed weight loss treatments including Mounjaro, Wegovy, and Saxenda, with a free clinical consultation completed in under 3 minutes. Our UK-registered prescribers assess your suitability and our prices are guaranteed to be the lowest in the UK — no hidden fees, no surprises.
Understanding Weight Loss Injection Costs in the UK
The monthly cost of weight loss injections varies significantly depending on the active ingredient, dose strength, and treatment phase. At Cured Pharmacy, Saxenda starts from £135.00, Wegovy from £135.00, and Mounjaro from £135.00 — all prices shown before you complete your consultation, ensuring complete transparency.
Unlike many online providers, we display exact pricing upfront rather than requiring you to complete lengthy forms before discovering costs. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription is clinically appropriate and competitively priced, with all medicines sourced directly from UK-licensed wholesalers [1].
Monthly costs typically increase as you progress through dose escalation schedules, which are designed to minimise side effects while optimising weight loss outcomes. Your UK prescriber will create a personalised titration plan during your free consultation, with clear pricing for each treatment phase.
Mounjaro (Tirzepatide): Dual-Action Weight Loss
Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK. This dual mechanism activates two complementary metabolic pathways simultaneously, producing superior weight loss compared to single-pathway treatments in head-to-head trials [2].
In the SURMOUNT-1 trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks — the highest efficacy observed in any obesity medication trial to date [2]. Patients also experienced significant improvements in cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers.
At Cured Pharmacy, Mounjaro treatment starts from £135.00 per month, with dose titration beginning at 2.5mg weekly and gradually increasing to your optimal maintenance dose. Each KwikPen contains four pre-measured doses for convenient once-weekly subcutaneous injection.
Who Can Use Mounjaro?
Mounjaro is licensed in the UK for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea. Your UK prescriber will assess your medical history, current medications, and weight loss goals during your free online consultation to determine suitability [3].
Wegovy (Semaglutide): Proven GLP-1 Therapy
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 to reduce appetite and increase feelings of fullness. Originally developed for type 2 diabetes management, semaglutide was subsequently licensed by the MHRA specifically for chronic weight management at higher therapeutic doses [4].
The STEP clinical trial programme demonstrated that participants on the 2.4mg maintenance dose achieved an average weight reduction of 14.9% over 68 weeks, with 86.4% of participants losing at least 5% of their baseline body weight [4]. Cardiovascular benefits were also observed, including reduced waist circumference and improved glycaemic control in patients with prediabetes.
Available at Cured Pharmacy from £135.00, Wegovy follows a gradual dose escalation schedule starting at 0.25mg weekly and increasing to the 2.4mg maintenance dose over 16-20 weeks. Each pre-filled FlexTouch pen delivers four weekly doses with a simple click-and-inject mechanism.
Wegovy vs Mounjaro: Key Differences
While both are once-weekly injections that suppress appetite through GLP-1 receptor activation, Mounjaro's dual GIP/GLP-1 mechanism typically produces greater absolute weight loss in clinical trials. However, Wegovy offers a lower entry price point and extensive long-term safety data from over a decade of semaglutide use in diabetes management. Your UK prescriber will discuss which option aligns best with your clinical profile and budget during your consultation.
| Treatment | Active Ingredient | Frequency | Starting Price |
|---|---|---|---|
| Mounjaro | Tirzepatide (dual GIP/GLP-1) | Once weekly | From £124.99 |
| Wegovy | Semaglutide (GLP-1) | Once weekly | From £69.00 |
| Saxenda | Liraglutide (GLP-1) | Daily injection | From £68.00 |
| Orlistat 120mg | Orlistat (lipase inhibitor) | Three times daily | From £32.00 |
| Xenical | Orlistat (lipase inhibitor) | Three times daily | From £32.00 |
Saxenda (Liraglutide): Daily Injection Option
Saxenda contains liraglutide, a shorter-acting GLP-1 receptor agonist requiring daily subcutaneous injection rather than weekly administration. First licensed in the UK in 2015, Saxenda offers the longest real-world safety record among GLP-1 weight loss treatments and is often preferred by patients who value gradual dose adjustments [5].
Clinical trials showed that patients on the 3.0mg daily maintenance dose achieved an average weight loss of 8.4 kg over 56 weeks, with 63.2% losing at least 5% of baseline body weight [5]. The daily injection schedule allows for more flexible dose titration, which some patients find helpful for managing gastrointestinal side effects.
Starting from £135.00 at Cured Pharmacy, Saxenda represents the most affordable entry point for prescription weight loss injections in the UK. Each multi-dose pen contains 30 doses, with treatment beginning at 0.6mg daily and increasing by 0.6mg increments weekly until reaching the 3.0mg maintenance dose.
Oral Weight Loss Treatments: Orlistat and Alternatives
For patients who prefer oral medication or have contraindications to injectable treatments, Orlistat offers a clinically proven alternative. Unlike GLP-1 medications that work centrally to reduce appetite, Orlistat acts locally in the digestive system to block approximately 30% of dietary fat absorption [6].
Available in both prescription-strength 120mg formulations (Xenical, generic Orlistat) and lower-dose 60mg over-the-counter options (Alli, Orlos), Orlistat is taken three times daily with meals containing fat. Clinical trials demonstrated an average weight loss of 2.9 kg more than diet and exercise alone over 12 months [6].
At Cured Pharmacy, generic Orlistat 120mg starts from £135.00, Xenical from £135.00, and Orlos 60mg from £135.00 — making oral treatments the most budget-friendly option for weight management. However, efficacy is generally lower than injectable GLP-1 therapies, and gastrointestinal side effects can be significant if dietary fat intake is not properly controlled.
Choosing Between Injectable and Oral Treatments
Injectable GLP-1 medications typically produce greater absolute weight loss but require subcutaneous administration and carry higher monthly costs. Oral Orlistat offers convenience and lower pricing but requires strict adherence to a reduced-fat diet and may cause troublesome gastrointestinal effects. Your UK prescriber will assess your lifestyle, budget, previous weight loss attempts, and medical history to recommend the most appropriate treatment pathway during your free consultation.
How to Access Cheapest Weight Loss Injections UK at Cured Pharmacy
All prescription weight loss treatments at Cured Pharmacy require a clinical assessment by a UK-registered prescriber, completed entirely online in under 3 minutes. Our streamlined consultation form collects your medical history, current medications, and weight management goals, which are then reviewed by our clinical team to determine the most suitable treatment option.
Once approved, your prescription is dispensed by our UK-registered pharmacy (GPhC 9012511) and dispatched in 100% discreet packaging via Royal Mail or courier service. We offer next-day delivery options for urgent orders, and all medicines are sourced exclusively from UK-licensed wholesalers to guarantee authenticity.
Our lowest price guarantee ensures you're getting the most competitive rates in the UK market. If you find a lower price for the same medication from another UK-registered online pharmacy, we'll match it. Prices are fixed and transparent — what you see on the product page is what you pay, with no hidden consultation fees or subscription charges.
Scientific References
- Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg solution for injection in pre-filled pen. GOV.UK. [accessed 13 August 2026]
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
- National Institute for Health and Care Excellence. (2023). Tirzepatide for treating overweight and obesity [ID6204]. NICE guidance in development. [accessed 13 August 2026]
- Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
- Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
- Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
- NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
- NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
- NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.
Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and weight loss outcomes depend on adherence to treatment, dietary modification, and lifestyle factors.
How it Works?
Select from our recommended UK-licensed medications.
1Choose your treatment

Select safe UK treatments. Quick answers.
2Answer quick questions

We will deliver direct to you as quickly as tomorrow.
3Get it delivered fast

Start Your Assessment For Weight Loss
Start your journey to better health today.
- Reviewed by UK-based prescribers
- Takes under 3 minutes
- Discreet Packaging
Start Your Journey To Better Health Today
Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.
Start My Assessment Log in to Your AccountFaq
Medically reviewed by
Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)
Reviewed on: June 03, 2026
Last updated on 13 August 2026.
Review History
Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.
Why this page was updated on 13 August 2026
Content checked and updated as part of our periodic review, to ensure accuracy and currentness.
Current version (13 August 2026)
Edited by: The Editorial Team
Medically reviewed by:
Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist
How we source info.
When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.


